-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Therapeutics Secures Exclusive Rights to Senlang CAR-T Platform Outside China

PUBT·11/11/2026 13:54:12
Listen to the news
Tempest Therapeutics Secures Exclusive Rights to Senlang CAR-T Platform Outside China
  • Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral platform, securing exclusive development and commercialization rights outside China.
  • The license covers in vivo CAR-T candidates, led by TPST-4903, a BCMA/GPRC5D dual-targeting treatment for relapsed or refractory multiple myeloma.
  • Preliminary Phase 1 observations in 13 patients supported the option exercise; additional follow-up is needed to assess benefits and risks.
  • The agreement, originally announced in September 2026, includes financial obligations and development requirements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110853PRIMZONEFULLFEED9875404) on November 11, 2026, and is solely responsible for the information contained therein.